Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study

被引：13

作者：

Yang, Zhongyin ^{[1
]}

Lu, Sheng ^{[1
]}

Shi, Min ^{[2
]}

Yuan, Hong ^{[2
]}

Wang, Zhenqiang ^{[1
]}

Ni, Zhentian ^{[1
]}

He, Changyu ^{[1
]}

Zheng, Yanan ^{[1
]}

Zhu, Zhenglun ^{[1
]}

Liu, Wentao ^{[1
]}

Yao, Xuexin ^{[1
]}

Zhang, Jun ^{[2
]}

Li, Chen ^{[1
]}

Yan, Min ^{[1
]}

Yan, Chao ^{[1
]}

Zhu, Zhenggang ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Digest Surg, Dept Gen Surg,Shanghai Key Lab Gastr Neoplasms,Sch, 197 Ruijin Er Rd, Shanghai, Peoples R China

[2] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Oncol, Shanghai, Peoples R China

来源：

GASTRIC CANCER | 2024年 / 27卷 / 02期

关键词：

Gastric cancer; Peritoneal metastasis; Intraperitoneal infusion; Conversion surgery; Oncological outcome; INTRAPERITONEAL CHEMOTHERAPY; GASTROESOPHAGEAL JUNCTION; KRUKENBERG TUMORS; PLUS CHEMOTHERAPY; OPEN-LABEL; PACLITAXEL; COMPLICATIONS; OXALIPLATIN; GASTRECTOMY; PHASE-3;

D O I：

10.1007/s10120-023-01452-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundData on the long-term oncological outcomes of patients who undergo conversion surgery (CS) in gastric cancer (GC) patients with peritoneal metastasis (PM) are limited.MethodsGC patients with PM who received intraperitoneal (ip) and systemic chemotherapy between April 2015 and January 2021 were enrolled. Multivariate analysis was performed to identify risk factors associated with survival. Clinicopathological and survival outcomes were compared between those with CS and those without CS (NCS). The paclitaxel (PTX) plus tegafur-gimeracil-oteracil potassium capsules (S-1) (PS) + ip PTX and oxaliplatin plus S-1 (SOX) + ip PTX groups were matched in a 1:1 ratio using propensity score matching. Oncological and survival data were collected and analyzed.ResultsA total of 540 patients who received ip chemotherapy via subcutaneous port and systemic chemotherapy were analyzed and 268 patients were enrolled, including 113 who underwent CS and 155 who did not. Overall survival (OS) were 27.0 months and 11.8 months in the CS and NCS groups (P < 0.0001), respectively. R0 resection was an independent prognostic factor for patients who underwent CS. The OS of patients with or without ovariectomy was 21.3 or 12.0 months (P < 0.0001). No difference of clinicopathological and survival outcomes was found between the PS + ip PTX and SOX + ip PTX groups.ConclusionConversion therapy is safe and adverse events were manageable. CS improves the survival of GC patients with PM after ip and systemic chemotherapy. R0 is an important prognostic factor. Furthermore, outcomes are comparable between the PS + ip PTX and SOX + ip PTX groups

引用

页码：235 / 247

页数：13

共 41 条

[1] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer [J].